Targeting mTOR Pathway in PTEN Deleted Newly Isolated Chordoma Cell Line

Article Multidisciplinary Sciences

Personalized chordoma organoids for drug discovery studies

Ahmad Al Shihabi et al.

Summary: This study successfully established patient-derived organoids from chordoma tumor samples and identified potential therapeutic targets, providing new directions for chordoma treatment.

SCIENCE ADVANCES (2022)

添加到收藏夹

Review Medical Laboratory Technology

Chordoma A Review and Differential Diagnosis

Veronica Ulici et al.

Summary: Chordoma is a clinically and histologically unique malignant neoplasm that requires the exclusion of many diagnostic considerations to establish the correct diagnosis. Treatment options have primarily focused on surgical excision with limited success; however, novel therapeutic options including targeted therapy and immunotherapy hold promise for improving prognosis.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Advances in the development of chordoma models for drug discovery and precision medicine

Robert L. Walker et al.

Summary: This review summarizes recent enhancements and improvements made to generate useful chordoma models and discusses their applications in drug discovery and precision medicine.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2022)

添加到收藏夹

Review Oncology

Emerging target discovery and drug repurposing opportunities in chordoma

Daniel M. Freed et al.

Summary: The development of effective and personalized treatment options for rare cancers like chordoma faces challenges due to limited genomic impact and low mutation burden. However, as our understanding of oncogenic mechanisms matures, new therapeutic opportunities arise beyond the tumor's genome. This review discusses how advanced tools and approaches are uncovering vulnerabilities in chordoma and highlights the identification and evaluation of new therapeutic hypotheses for this rare cancer through emerging observations and convergence with other cancers.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Surgery

PTEN is recognized as a prognostic-related biomarker and inhibits proliferation and invasiveness of skull base chordoma cells

Kaibing Tian et al.

Summary: This study explored the function of PTEN in skull base chordoma (SBC) at the clinical and cellular levels. The results showed that decreased PTEN expression was associated with reduced progression-free survival (PFS) in SBC patients, and PTEN knockdown led to enhanced cell proliferation and invasion in chordoma cells.

FRONTIERS IN SURGERY (2022)

添加到收藏夹

Review Medicine, General & Internal

Chordoma-Current Understanding and Modern Treatment Paradigms

Sean M. Barber et al.

Summary: Chordoma is a malignant and challenging low-grade notochordal tumor, with extent of surgical resection and adequacy of surgical margins being crucial prognostic factors. Ongoing research focuses on potential molecular therapy targets for improved outcomes.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Medicine, Research & Experimental

mTORC1 promotes malignant large cell/anaplastic histology and is a targetable vulnerability in SHH-TP53 mutant medulloblastoma

Valentina Conti et al.

Summary: mTORC1 hyperactivation is associated with unfavorable histological features in p53-mutant SHH MB patients, and inhibiting mTORC1 can reduce tumor burden and aggressiveness, potentially serving as a specific druggable target for this subset of MB.

JCI INSIGHT (2021)

添加到收藏夹

Review Pathology

The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives

Marta Sbaraglia et al.

Summary: Mesenchymal tumors, especially those in challenging diagnostic pathology, are greatly impacted by the refinement of classification schemes as it improves the quality of pathologic diagnosis and therapeutic options. The recent 2020 WHO classification of Soft Tissue Tumours and Bone, open to expert clinicians, has stimulated a debate on the importance of pathologic diagnosis and precision oncology. Pathologic diagnosis, integrating morphologic, immunohistochemical and molecular characteristics, plays a crucial role in clinical decision making and the WHO classification serves as a key instrument in promoting multidisciplinary efforts for more effective treatments.

PATHOLOGICA (2021)

添加到收藏夹

Article Oncology